ESR1 and breast cancer: Indeed, ERα and PgR status is assessed by means of IHC, which evaluates the proportion of tumor cells expressing ERα or PgR, and which dichotomizes BC cells as HR+ or HR− based on a cut-off point of 1% for both proteins [94].